Podcast appearances and mentions of Dawn L Hershman

Host: Matt Birnholz, MD Guest: Dawn L. Hershman, MD, MS Much of the focus on endocrine therapy tends to be around future directions and what new treatments are going to accelerate care for breast cancer patients. But oncologists need to take stock of how physically and financially costly it can be, as Dr. Dawn Hershman explains to Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Dawn L. Hershman, MD, MS Much of the focus on endocrine therapy tends to be around future directions and what new treatments are going to accelerate care for breast cancer patients. But oncologists need to take stock of how physically and financially costly it can be, as Dr. Dawn Hershman explains to Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Dawn L. Hershman, MD, MS Much of the focus on endocrine therapy tends to be around future directions and what new treatments are going to accelerate care for breast cancer patients. But oncologists need to take stock of how physically and financially costly it can be, as Dr. Dawn Hershman explains to Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Dawn L. Hershman, MD, MS Much of the focus on endocrine therapy tends to be around future directions and what new treatments are going to accelerate care for breast cancer patients. But oncologists need to take stock of how physically and financially costly it can be, as Dr. Dawn Hershman explains to Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Host: Matt Birnholz, MD Guest: Dawn L. Hershman, MD, MS Much of the focus on endocrine therapy tends to be around future directions and what new treatments are going to accelerate care for breast cancer patients. But oncologists need to take stock of how physically and financially costly it can be, as Dr. Dawn Hershman explains to Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Dawn L. Hershman, MD, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, discusses the disparities and challenges in adherence to oral antineoplastic agents.